Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20139789 | 0.95 | MAPT (0.56) | MEN1KMT2APDK2MAPTSMN1; SMN2 | |
| SCHEMBL31111852 | 0.91 | PDK2 (0.53) | MEN1KMT2APDK2MAPTSMN1; SMN2 | |
| SCHEMBL5234283 | 0.89 | PDK2 (0.55) | MEN1KMT2APDK2MAPTSMN1; SMN2 | |
| SCHEMBL30567184 | 0.89 | PDK2 (0.55) | MEN1KMT2APDK2MAPTSMN1; SMN2 | |
| SCHEMBL21533464 | 0.88 | MEN1 (0.65) | MEN1KMT2APDK2MAPTSMN1; SMN2 | |
| SCHEMBL5229994 | 0.87 | PDK2 (0.53) | MEN1KMT2APDK2MAPTSMN1; SMN2 | |
| SCHEMBL24511558 | 0.85 | MAPT (0.56) | MEN1KMT2APDK2MAPTSMN1; SMN2 | |
| SCHEMBL1257264 | 0.85 | MEN1 (0.70) | MEN1KMT2APDK2MAPTSMN1; SMN2 | |
| SCHEMBL3486882 | 0.85 | GPR119 (0.65) | MAPTNPSR1GPR119 | |
| SCHEMBL1778970 | 0.85 | PDK2 (0.47) | MEN1KMT2APDK2MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219234-A1 | Thienopyridine Derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1764367-A1 | THIENOPYRIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219234-A1 | Thienopyridine Derivatives | RASGRP1, NRAS, HRH3 | MEN1 975/4885KMT2A 2660/4885PDK2 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.